Quinupramine
Clinical data
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Elimination half-life33 hours
Identifiers
  • (±)-11-quinuclidin-3-yl-5,6-dihydrobenzo[b][1]benzazepine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ECHA InfoCard100.046.149 Edit this at Wikidata
Chemical and physical data
FormulaC21H24N2
Molar mass304.437 g·mol−1

Quinupramine (brand names Kevopril, Kinupril, Adeprim, Quinuprine) is a tricyclic antidepressant (TCA) used in Europe for the treatment of depression.[1][2]

Pharmacologically, quinupramine acts in vitro as a strong muscarinic acetylcholine receptor antagonist (anticholinergic) and H1 receptor antagonist (antihistamine), moderate 5-HT2 receptor antagonist, and weak serotonin and norepinephrine reuptake inhibitor.[3] It has negligible affinity for the α1-adrenergic, α2-adrenergic, β-adrenergic, or D2 receptor.[3]

Clinically, quinupramine is reported to be stimulating similarly to imipramine, desipramine, and demexiptiline.[4] It can be inferred that its in vivo metabolites may have stronger effects on the reuptake of norepinephrine and/or serotonin than quinupramine itself.[citation needed]

References

  1. ^ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. p. 908. ISBN 3-88763-075-0.
  2. ^ Vela JM, Buschmann H, Holenz J, Párraga A, Torrens A (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. p. 248. ISBN 978-3-527-31058-6.
  3. ^ a b Sakamoto H, Yokoyama N, Kohno S, Ohata K (December 1984). "Receptor binding profile of quinupramine, a new tricyclic antidepressant". Japanese Journal of Pharmacology. 36 (4): 455–460. doi:10.1254/jjp.36.455. PMID 6098759.
  4. ^ Kent A, Billiard M (2003). Sleep: physiology, investigations, and medicine. New York: Kluwer Academic/Plenum. p. 233. ISBN 0-306-47406-9.
Categories